The FDA's Vaccines And Related Biological Products Advisory Committee will meet tomorrow to discuss the safety of and efficacy of Gardasil, Merck's vaccine to protect against human papillomavirus (HPV), an important cause of cervical cancer. The draft agenda is online, along with briefing documents, and FDA and consultant rosters for the meeting. The final briefing document (PDF) provides a considerable amount of information on HPV infection and Gardasil. According to the CNN article, the committee will make a recommendation with regards to approving the vaccine, and an FDA decision is expected by June 8.
(See previous post for additional background on the vaccine, HPV, and cervical cancer)
No comments:
Post a Comment